Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CareDx Inc Market Cap
Based on ratings from 3 stock analysts, the CareDx Inc stock price is expected to increase by 16.04% in 12 months. This is calculated by using the average 12-month stock price forecast for CareDx Inc. The lowest target is $25 and the highest is $40. Please note analyst price targets are not guaranteed and could be missed completely.
CareDx Inc has a total of 3 Wall St Analyst ratings. There are 3 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that CareDx Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CDNA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brandon Couillard Wells Fargo | Underweight | $28 | Initiates | Aug 27, 2024 |
| Sung Ji Nam BTIG | Buy | $40 | Upgrade | Aug 19, 2024 |
| Connor Chamberlain Craig-Hallum | Buy | $32 | Maintains | Aug 1, 2024 |
| Matthew Sykes Goldman Sachs | Buy | $26 | Maintains | Aug 1, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | Reiterates | Aug 1, 2024 | |
| Matthew Sykes Goldman Sachs | Buy | $16 | Maintains | Jul 17, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | Reiterates | May 31, 2024 | |
| Connor Chamberlain Craig-Hallum | Buy | $22 | Maintains | May 17, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | Reiterates | May 15, 2024 | |
| Mason Carrico Stephens & Co. | Overweight | $18 | Maintains | May 13, 2024 |
| Andrew Cooper Raymond James | Market Perform | Downgrade | May 13, 2024 | |
| Matthew Sykes Goldman Sachs | Buy | $14 | Maintains | May 13, 2024 |
| Connor Chamberlain Craig-Hallum | Buy | $15 | Reiterates | May 9, 2024 |
| Alexander Nowak Craig-Hallum | Buy | $15 | Upgrade | May 1, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $15 | Reiterates | Apr 17, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $10 | Upgrade | Nov 9, 2023 |
| Mason Carrico Stephens & Co. | Equal-Weight | $10 | Reiterates | Sep 26, 2023 |
| Andrew Cooper Raymond James | Outperform | $12 | Upgrade | Aug 15, 2023 |
| Yi Chen HC Wainwright & Co. | Neutral | Reiterates | Aug 9, 2023 | |
| Andrew Cooper Raymond James | Market Perform | Maintains | Jul 11, 2023 |
When did it IPO
2014
Staff Count
635
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. John Walter Hanna Jr.
Market Cap
$1.68B
In 2023, CDNA generated $280.3M in revenue, which was a decrease of -12.89% from the previous year. This can be seen as a signal that CDNA's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CareDx, Inc. has appointed two senior executives to drive key initiatives as part of its long-term growth strategy, which will be detailed at an Investor Day in October 2024.
Why It Matters - The appointment of senior executives and the upcoming Investor Day signal CareDx's commitment to growth and innovation, potentially influencing stock performance and investor confidence.
Fri, 16 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CareDx, Inc. announced that CMS plans to retire a draft LCD restricting coverage for non-invasive blood-based testing for allograft rejection, enhancing long-term coverage prospects.
Why It Matters - CareDx’s potential expanded coverage for non-invasive testing could lead to increased sales and market share, positively impacting its financial performance and stock value.
Fri, 09 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - CareDx (CDNA) reaches a 52-week high, prompting an evaluation of its fundamentals to assess potential for future gains.
Why It Matters - CareDx's 52-week high signals strong market performance, but assessing its fundamentals helps investors gauge potential future growth and risks.
Wed, 07 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - CareDx (CDNA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects, potentially driving its stock price higher.
Why It Matters - Growing optimism and a Strong Buy rating suggest potential stock price appreciation for CareDx, indicating favorable earnings prospects that could attract investor interest.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - CareDx, Inc. (NASDAQ: CDNA) will hold its Q2 2024 earnings conference call on July 31, 2024, at 4:30 PM ET, featuring key company executives.
Why It Matters - CareDx's earnings call provides insights into financial performance and strategic direction, crucial for assessing the company's growth potential and investment viability.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CareDx, Inc. reported Q2 2024 revenue of $92.3M, up 31% YoY. Testing volume increased 17% to 43,700 tests. GAAP net loss was $1.4M, while non-GAAP net income was $13.6M. Adjusted EBITDA was $12.9M.
Why It Matters - CareDx's 31% revenue growth and increased testing volume indicate strong demand and operational efficiency, while the shift to positive adjusted EBITDA suggests improving profitability, attracting investor interest.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
